New York, US – January 22, 2019 – Creative Biolabs, a supplier-of-choice for scientists across the globe, launches a series of BsAb manufacturing services including hybrid-hybridoma technology by the somatic fusion of two different hybridoma cell lines; chemical conjugation based on chemical crosslinkers; and genetic methods using recombinant DNA technology.
Genetic Engineering Technology
It is a powerful technology that has promoted the creation of second-generation bispecific molecules of different sizes and binding strengths and enables to produce recombinant BsAbs of defined composition with enhanced stability and producibility by modulation of valency and size. Base on this technology, Creative Biolabs can generate structurally and functionally defined molecules including IgG-like molecules, appended IgGs, BsAb fragments and bispecific fusion proteins. Moreover, BsAb humanization or fully human BsAbs can be implemented to reduce immunogenicity.
Chemical conjugation services in Creative Biolabs mainly include the selection of mAbs and antibody fragments, the design of an appropriate conjugation strategy (a suitable crosslinker and an optimal chemical reaction system), the scale-up production, purification and characterization. In the conjugation protocols, Creative Biolabs provides homobifunctional cross-linkers such as DTNB, PDM, or heterobifunctional cross-linkers such as SPDP/DTT and Traut’s reagent/SMCC, to facilitate chemical coupling of two parental antibodies obtained from recombinant expression or hybridomas. Meanwhile, other special linkers or antibodies provided by clients are also available to develop a customized BsAb.
It has long been an outstanding and indispensable platform for producing high-quality monoclonal antibodies (mAbs). At the early stage of BsAb development, somatic hybridization of two hybridomas is widely used. By hybrid-hybridoma, Creative Biolabs mainly created IgG-like molecules, which generally have longer serum half-lives than bispecific fragments, and maintain Fc-mediated effector functions, including antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cell-mediated cytotoxicity (ADCC), as well as complement-dependent cytotoxicity (CDC).
With the rapid development of recombinant protein technology, numerous BsAbs have emerged as therapeutic proteins. Based on the well-established cell lines, Creative Biolabs are confident to help customers obtain high affinity bispecific antibodies (BsAbs) for both academic and industrial purposes in a time-saving manner. Please visit https://www.creative-biolabs.com/bsab/ for more information on BsAbs.
Creative Biolabs was established in 2004 by scientists who are dedicated to conquering of cancer. Over the past 10 years, Creative Biolabs has grown into a recognized world leader in antibody (rAb) discovery, engineering, production, and analysis. Standing on the shoulder of a giant, the bispecific antibody (BsAb) team has a collective of experienced scientists committed to providing high-quality services to customers all over the world. Now, with the cutting-edge platforms and methods (quadroma development, chemical conjugation, and genetic engineering), a comprehensive list of bispecific antibody products is available to customers in academia and industry fields.
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States